On December 14, 2022, Longview Acquisition Corp. II's stockholders approved amendments to its Charter and Investment Trust Management Agreement. The amendments extend the deadline for completing a business combination to September 23, 2023. Following the amendments, stockholders redeemed 60,932,798 Public Shares for around $612.98 million, leaving 8,067,202 shares outstanding. The company plans to redeem all remaining Public Shares due to an inability to finalize a business combination by the new deadline and will begin the liquidation process. The securities are expected to be delisted from NYSE.
HeartFlow Holding, Inc. and Longview Acquisition Corp. II have announced a definitive merger agreement, aiming to enhance precision heart care. The merger will create HeartFlow Group, Inc., anticipated to list under HFLO. The transaction is valued at approximately $2.4 billion and is expected to provide $400 million in growth capital. HeartFlow specializes in non-invasive cardiac testing, targeting a market worth $10 billion, with plans to expand it to over $50 billion. The merger is set to close in Q4 2021, pending stockholder approval.
Summary not available.
Longview Acquisition Corp. II (NYSE: LGV.U) announced that starting May 10, 2021, holders of its initial public offering units (69 million units) can separately trade shares of Class A common stock (symbol: LGV) and redeemable warrants (symbol: LGV WS). Units not separated will continue to trade under the symbol LGV.U. The offering was underwritten by UBS and Cowen. The SEC approved a registration statement for these securities earlier on March 18, 2021. The company, focusing on healthcare and other sectors, aims to create value for shareholders through strategic partnerships.